LBRX catalyst calendar

LB PHARMACEUTICALS INC

Upcoming catalysts
4
Cash runway
42.2 months
Cash & investments
$328M
Phase 3 programs
2

LB PHARMACEUTICALS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 10, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.

Cash runway is approximately 42.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 10, 2026 est. Next quarterly earnings (projected) Earnings —
June 15, 2027 Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia Trial Milestone Phase 3
February 15, 2028 Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. Trial Milestone Phase 2
December 15, 2028 52-week Open Label Safety-Tolerability Study Trial Milestone Phase 3

Track LBRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open LBRX in the tracker

Recent history

DateEventTypePhase
September 15, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
September 3, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
August 11, 2026 Quarterly results filed (8-K) Earnings —
July 29, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
July 22, 2026 8-K filed: Other event Filing —
June 10, 2026 8-K filed: Leadership change Corporate —
May 12, 2026 Quarterly results filed (8-K) Earnings —
March 26, 2026 Quarterly results filed (8-K) Earnings —
March 16, 2026 8-K filed: Leadership change Corporate —
March 10, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
February 5, 2026 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
November 13, 2025 8-K filed: Material agreement Corporate —
November 12, 2025 8-K filed: Other event Filing —
November 6, 2025 Quarterly results filed (8-K) Earnings —
December 4, 2024 Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia Trial Milestone Phase 2
September 17, 2021 Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers Trial Milestone Phase 1
July 1, 2020 Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.